首页> 美国卫生研究院文献>Antimicrobial Agents and Chemotherapy >Efficacy of the Antiadhesin Octyl O-(2-Acetamido-2-Deoxy-β-d- Galactopyranosyl)-(1-4)-2-O-Propyl-β-d-Galactopyranoside (Fimbrigal-P) in a Rat Oral Candidiasis Model
【2h】

Efficacy of the Antiadhesin Octyl O-(2-Acetamido-2-Deoxy-β-d- Galactopyranosyl)-(1-4)-2-O-Propyl-β-d-Galactopyranoside (Fimbrigal-P) in a Rat Oral Candidiasis Model

机译:抗粘附素辛基O-(2-乙酰氨基-2-脱氧-β-d-吡喃半乳糖基)-(1-4)-2-O-丙基-β-d-吡喃半乳糖苷(Fimbrigal-P)在大鼠口腔念珠菌病中的功效模型

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

Adherence of Candida albicans to buccal epithelial cells via its fimbrial subunit requires the minimal disaccharide sequence β-GalNAc(1-4)-β-galactosidase in host cell receptors asialo-GM1 or asialo-GM2. This and other disaccharides and some of its synthetic derivatives have been shown to inhibit purified fimbrial or pathogen binding in vitro. This study evaluates the in vivo efficacy of the propyl derivative of this disaccharide, octyl O-(2-acetamido-2-deoxy-β-d-galactopyranosyl)-(1-4)-2-O-propyl-β-d-galactopyranoside, or Fimbrigal-P, incorporated into a mucoadhesive polymer formulation in a rat oral candidiasis model. Colony counts of microcurette samples from the oral cavity and tongue homogenates were used to estimate the effectiveness of four treatment modalities to reduce oral fungal burden. All treatment modalities (preventative, premixing with the Candida inoculant, drinking water, and treatment) significantly reduced fungal burden compared to untreated control animals by day 9; however, the preventative and premixing approaches provided a faster rate of fungal clearance. The low toxicity and immunogenicity of this synthetic carbohydrate and its stability in saliva, as demonstrated by high-performance liquid chromatography, make it a promising candidate for the prevention and treatment of microbial infections in which the pathogen relies on the β-GalNAc(1-4)-β-galactosidase disaccharide to establish adherence.
机译:白色念珠菌通过其纤维亚基粘附到颊上皮细胞需要宿主细胞受体无唾液酸GM1或无唾液酸GM2中的最小二糖序列β-GalNAc(1-4)-β-半乳糖苷酶。已经显示出该二糖和其他二糖及其某些合成衍生物在体外抑制纯化的纤维或病原体结合。该研究评估了该二糖的丙基衍生物辛基O-(2-乙酰氨基-2-脱氧-β-d-吡喃半乳糖基)-(1-4)-2-O-丙基-β-d-的体内功效将半乳糖吡喃糖苷或Fimbrigal-P掺入大鼠口腔念珠菌病模型的粘膜粘附聚合物制剂中。来自口腔和舌头匀浆的微刮匙样品的菌落计数被用来评估四种治疗方法减轻口腔真菌负担的有效性。与未治疗的对照动物相比,所有治疗方式(预防,与念珠菌接种物预混合,饮用水和治疗)在第9天时均显着降低了真菌负担;然而,预防和预混方法提供了更快的真菌清除率。高效液相色谱法证明了这种合成碳水化合物的低毒性和免疫原性及其在唾液中的稳定性,使其成为预防和治疗病原体依赖于β-GalNAc(1- 4)-β-半乳糖苷酶双糖建立依从性。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号